Elanco Animal Health Incorporated (NYSE:ELAN) Shares Acquired by Geode Capital Management LLC

Geode Capital Management LLC grew its holdings in Elanco Animal Health Incorporated (NYSE:ELAN - Free Report) by 4.0% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 8,180,840 shares of the company's stock after acquiring an additional 312,165 shares during the period. Geode Capital Management LLC owned 1.65% of Elanco Animal Health worth $99,102,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also modified their holdings of ELAN. JPMorgan Chase & Co. raised its holdings in Elanco Animal Health by 76.6% in the 3rd quarter. JPMorgan Chase & Co. now owns 10,057,656 shares of the company's stock worth $147,747,000 after purchasing an additional 4,361,799 shares during the period. Norges Bank bought a new position in shares of Elanco Animal Health in the fourth quarter worth about $47,424,000. Brandes Investment Partners LP lifted its position in shares of Elanco Animal Health by 66.9% during the 4th quarter. Brandes Investment Partners LP now owns 5,731,180 shares of the company's stock valued at $69,405,000 after buying an additional 2,296,691 shares in the last quarter. Magnetar Financial LLC boosted its position in shares of Elanco Animal Health by 13.7% in the fourth quarter. Magnetar Financial LLC now owns 12,032,325 shares of the company's stock worth $145,711,000 after purchasing an additional 1,454,082 shares during the period. Finally, Prudential Financial Inc. boosted its holdings in Elanco Animal Health by 40.4% in the 4th quarter. Prudential Financial Inc. now owns 4,224,997 shares of the company's stock worth $51,165,000 after buying an additional 1,214,992 shares during the period. Hedge funds and other institutional investors own 97.48% of the company's stock.

Elanco Animal Health Stock Down 2.0 %

NYSE ELAN traded down $0.18 on Tuesday, hitting $8.51. The stock had a trading volume of 780,629 shares, compared to its average volume of 4,884,427. Elanco Animal Health Incorporated has a 52-week low of $8.03 and a 52-week high of $18.80. The business's fifty day moving average price is $10.52 and its 200 day moving average price is $11.98. The company has a debt-to-equity ratio of 0.66, a current ratio of 2.55 and a quick ratio of 1.31. The stock has a market cap of $4.22 billion, a price-to-earnings ratio of 21.27, a price-to-earnings-growth ratio of 2.50 and a beta of 1.44.

Elanco Animal Health (NYSE:ELAN - Get Free Report) last announced its earnings results on Tuesday, February 25th. The company reported $0.14 earnings per share for the quarter, missing the consensus estimate of $0.15 by ($0.01). Elanco Animal Health had a return on equity of 6.78% and a net margin of 4.60%. The business had revenue of $1.02 billion for the quarter, compared to analysts' expectations of $1.01 billion. During the same quarter last year, the firm earned $0.08 earnings per share. The firm's quarterly revenue was down 1.4% compared to the same quarter last year. Equities research analysts anticipate that Elanco Animal Health Incorporated will post 0.91 earnings per share for the current year.

Analyst Ratings Changes

A number of research firms recently commented on ELAN. Barclays lowered their price target on Elanco Animal Health from $20.00 to $19.00 and set an "overweight" rating on the stock in a report on Wednesday, February 26th. Stifel Nicolaus lowered their price target on Elanco Animal Health from $15.00 to $13.00 and set a "buy" rating for the company in a report on Monday. UBS Group dropped their target price on shares of Elanco Animal Health from $18.00 to $17.00 and set a "buy" rating on the stock in a report on Wednesday, February 26th. Morgan Stanley lowered their price target on shares of Elanco Animal Health from $14.00 to $13.00 and set an "equal weight" rating for the company in a research report on Wednesday, February 26th. Finally, Piper Sandler dropped their target price on Elanco Animal Health from $16.00 to $12.00 and set a "neutral" rating on the stock in a research report on Thursday, March 6th. Four analysts have rated the stock with a hold rating and three have given a buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of "Hold" and an average target price of $14.67.

Insider Activity at Elanco Animal Health

In other news, Director Lawrence Erik Kurzius bought 10,000 shares of Elanco Animal Health stock in a transaction that occurred on Tuesday, March 11th. The stock was bought at an average price of $10.20 per share, for a total transaction of $102,000.00. Following the purchase, the director now directly owns 111,459 shares of the company's stock, valued at approximately $1,136,881.80. The trade was a 9.86 % increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. 0.57% of the stock is currently owned by insiders.

About Elanco Animal Health

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.